International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA in Patients with AA Amyloidosis

Trial Profile

International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA in Patients with AA Amyloidosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Amyloid A amyloidosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Auven Therapeutics
  • Most Recent Events

    • 28 Feb 2017 Status changed from recruiting to discontinued, according to a BELLUS Health media release. The company has decided to discontinue the development of Eprodisate for Amyloid-A-amyloidosis based on the results from a phase III study (Profile 700238113).
    • 30 Jul 2016 This trial was discontinued in Poland (end date: 2016-06-20) according to European Clinical Trials Database record.
    • 02 Jul 2016 The trial was prematurely ended in Lithuania (end date: 2016-06-20).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top